Trade Names:Feldene- Capsules 10 mg- Capsules 20 mgAlti-Piroxicam (Canada)Apo-Piroxicam (Canada)Gen-Piroxicam (Canada)Novo-Pirocam (Canada)Nu-Pirox (Canada)
Decreases inflammation, pain, and fever, probably through inhibition of cyclooxygenase activity and prostaglandin synthesis.
Slight delay in the rate of absorption with food. Steady state is 7 to 12 days, up to 2 to 3 wk. T max is 3 to 5 h. Well absorbed. C max is 3 to 8 mcg/mL (multiple doses), 1.5 to 2 mcg/mL (single doses).
Vd is 0.14 L/kg. Protein binding is 99%. Excreted in breast milk.
In the liver by hydroxylation; no active metabolites.
The t 1/2 is approximately 50 h. Eliminated primarily in the urine, small amount in feces; 5% excreted unchanged.
Therapeutic effect is 3 to 5 h.
Effect not established; however, the drug is extensively metabolized in the liver and may require reduced doses.
Treatment of acute or long-term use of rheumatoid arthritis and osteoarthritis.
Symptomatic relief of primary dysmenorrhea, pain, sunburn, juvenile rheumatoid arthritis.
Known allergy or hypersensitivity to aspirin, iodides, or any NSAID, including piroxicam.
PO Initiate and maintain at 20 mg/day in 1 to 2 divided doses.
Store at room temperature.
May augment risk of GI bleeding.Anticoagulants
May increase effect of anticoagulants because of decreased plasma protein binding and inhibition of platelet aggregation. May increase risk of gastric erosion and bleeding.Beta-blockers
Antihypertensive effect may be decreased.Cholestyramine
Effects of piroxicam may be decreased.Lithium
May decrease lithium Cl.Methotrexate
May increase methotrexate levels and toxicity.Ritonivir
May increase concentrations and possibly the toxicity of piroxicam by inhibiting its metabolism.
May prolong bleeding time. May reversibly increase BUN and serum creatinine.
Edema; weight gain; CHF; alterations in BP; vasodilation; palpitations; tachycardia.
Headache; malaise; dizziness; somnolence; vertigo; depression; insomnia; nervousness.
Pruritus; rash; sweating; erythema; bruising; desquamation; erythema multiforme; toxic epidermal necrolysis.
Tinnitus; swollen eyes; blurred vision; eye irritation; rhinitis; pharyngitis.
Epigastric distress; nausea; vomiting; anorexia; constipation; stomatitis; abdominal discomfort; diarrhea; flatulence; abdominal pain; indigestion; toxicity (bleeding, ulceration, perforation); heartburn; dyspepsia; anorexia.
Hematuria; proteinuria; increased BUN and serum creatinine; acute renal insufficiency and failure; papillary necrosis; interstitial nephritis; nephrotic syndrome; hyperkalemia; hyponatremia.
Increased bleeding time; decreased Hgb and Hct; anemia; leukopenia; eosinophilia, thrombocytopenia.
Increased LFTs; elevated liver enzymes.
Bronchospasm; laryngeal edema; dyspnea; hemoptysis; shortness of breath.
Category C .
Safety and efficacy not established.
Increased risk of adverse reactions. May require decreased dosage.
In certain patients (aspirin-allergic, nasal polyps) may precipitate asthma attacks.
May worsen CHF and hypertension.
Increases risk of bleeding.
Combination of dermatologic/allergic signs and symptoms (ie, arthralgias, pruritus, fever, fatigue, rash including vesiculobullous reactions, exfoliative dermatitis) suggestive of serum sickness have occurred.
Serious GI toxicity can occur at any time, with or without warning symptoms.
Drug may accumulate, increasing the risk of toxicity. In cases of advanced kidney disease, treatment with piroxicam is not recommended.
Drowsiness, dizziness, mental confusion, disorientation, lethargy, paresthesia, numbness, vomiting, GI irritation, headache, tinnitus, seizure, increased BUN.
Copyright © 2009 Wolters Kluwer Health.